◀ Back to ATP5O

ATP5O — BCRP3

Text-mined interactions from Literome

Han et al., Eur J Pharm Sci 2008 : These findings underscore the potential of methoxylated and hydroxylated chalcones as selective and potent inhibitors of BCRP whose mode of action may not involve the inhibition of ATPase activity
Vaidya et al., Mol Pharm 2009 : DNP-SG efflux decreased by 69.1 ( +/-11.3 ) %, 51.1 ( +/-5.4 ) %, 56.7 ( +/-8.3 ) % and 53.6 ( +/-10.8 ) % ( p < 0.05 ) in the presence of 5 mM sodium orthovanadate ( ATPase inhibitor ), 100 microM MK571 ( MRP-inhibitor ), 1 mM dipyridamole ( BCRP/P-gp/MRP1-inhibitor ) and 100 microM verapamil ( P-gp/MRP1 inhibitor ) respectively, without any change in DNP-SG formation, total tissue glutathione, GSH/GSSG ratio, tissue integrity or tissue viability